DMAC News and Press, DiaMedica Therapeutics Inc. From 11/10/25

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that Rick Pauls, President and CEO, will participate in the Jefferies Global Healthca...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its third quarter 2025 financial results will be released after the markets close on Wednesday, November 1...

2025-09-30 20:22:39 ET This article is part of a series that provides an ongoing analysis of the changes made to Leon Cooperman’s 13F stock portfolio on a quarterly basis. It is based on his regulatory 13F Form filed on 08/14/2025. The 13F portfolio value increased from ~$2.5...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that on September 18, 2025, it granted stock options to purchase an aggregate of 490,...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke, today announced that Rick Pauls, President and CEO, and Dave Wambeke, Chief Business Officer, will p...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that Rick Pauls, President and CEO, and Dave Wambeke, Chief Business Officer, will pa...

2025-08-13 15:58:25 ET The last time I wrote an article on DiaMedica Therapeutics Inc. ( DMAC ) it was with respect to a Seeking Alpha article entitled "DiaMedica: Early 2025 Interim Futility Analysis Could Be A Major Inflection Point." In that article, I spoke in detail abo...

2025-08-13 11:37:01 ET More on DiaMedica Therapeutics DiaMedica Therapeutics Inc. (DMAC) Q2 2025 Earnings Call Transcript DiaMedica Therapeutics appoints Julie Krop as Chief Medical Officer DiaMedica Therapeutics raises $30 million in private placement Seekin...

2025-08-13 11:36:21 ET DiaMedica Therapeutics Inc. (DMAC) Q2 2025 Earnings Conference Call August 13, 2025, 8:00 AM ET Company Participants Dietrich John Pauls - President, CEO & Director Julie Krop - Chief Medical Officer Scott Kellen - CFO & Corporate S...

2025-08-12 16:19:53 ET More on DiaMedica Therapeutics DiaMedica Therapeutics appoints Julie Krop as Chief Medical Officer DiaMedica Therapeutics raises $30 million in private placement Seeking Alpha’s Quant Rating on DiaMedica Therapeutics Historical e...